SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Jul 17, 2017

Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: July 17, 2017 · CIK: 0001130166 · Accession: 0001571049-17-006730

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-218305

Date

July 17, 2017

Author

Nicholas Stergis

Form

CORRESP

Company

Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)

Letter

Ladenburg Thalmann & Co. Inc.

4400 Biscayne Blvd, 14th Floor

Miami, FL 33137

July 17, 2017

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Re: CYCLACEL PHARMACEUTICALS, INC.

Registration Statement on Form S-1 (Registration No. 333-218305)

Concurrence in Acceleration Request

Ladies and Gentlemen:

Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Cyclacel Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 p.m. (Eastern Time), or as soon as practicable thereafter, on July 17, 2017, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
LADENBURG THALMANN & CO. INC.

Show Raw Text

CORRESP
1
filename1.htm

Ladenburg Thalmann & Co. Inc.

4400 Biscayne Blvd, 14th Floor

Miami, FL 33137

July 17, 2017

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

    Re:
    CYCLACEL PHARMACEUTICALS, INC.

    Registration Statement on Form S-1 (Registration No. 333-218305)

    Concurrence in Acceleration Request

Ladies and Gentlemen:

Ladenburg
Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering,
hereby concurs in the request by Cyclacel Pharmaceuticals, Inc. that the effective date of the above-referenced registration
statement be accelerated to 5:15  p.m. (Eastern Time), or as soon as practicable thereafter, on July 17, 2017, pursuant to
Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in
connection with this offering.

    Very truly yours,

    LADENBURG THALMANN & CO. INC.

    By:
    /s/ Nicholas Stergis

    Name: Nicholas Stergis

    Title: Managing Director

SecProbe.io